Company: IMNN
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0001641172-25-014324
Chunk: 35

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 35
---
17/2023  |     |                             |        |    |     |               | 26,667 |     |               |  13,333 | -1 |     | $         |  1.32 |     | 3/17/2033  |
|                       |     | 3/15/2024  |     |                             |        |    |     |               | 12,500 |     |               |  12,500 | -2 |     | $         |  0.86 |     | 3/15/2034  |
|                       |     | 6/12/2024  |     |                             |        |    |     |               | 12,500 |     |               |  12,500 | -2 |     | $         |  1.22 |     | 6/12/2034  |
|                       |     | 9/6/2024   |     |                             |        |    |     |               | 20,327 |     |               |  20,327 | -2 |     | $         |  1.04 |     | 9/6/2034   |

| (1) | Each                                                                                                                                
 of these stock option grants vest in three equal installments, with one-third of the grant vesting each immediately, on the first   
 anniversary, and on the second anniversary of the date of grant.                                                                    |
| (2) | Each                                                                                                                                
 of these stock option grants vest one half of the grant vesting on date of grant and one-fourth on the first and second anniversary 
 of the date of grant.                                                                                                               |
| (3) | Dr.                                                                                                                                 
 Lindborg received a restricted stock grant, which vests fully on the first anniversary of date of the grant.                        |

2024 Option Exercises and Stock Vested

During 2024, none of the Named Executive Officers exercised any of their vested stock options.

| 29 |

Pay Versus Performance

The following table reports the compensation of our principal executive officer (PEO) and the average compensation of the other named executive officers (Other NEOs) as reported in the Summary Compensation Table for the past three fiscal years, as well as their “compensation actually paid” as calculated pursuant to recently adopted SEC rules and certain performance measures required by the rules, including total stockholder return (“TSR”).

|         | Year (1)(2) |